ixekizumab (Taltz)
Jump to navigation
Jump to search
Indications
- chronic plaque psoriasis (FDA-approved March 2016)[2]
- psoriatic arthritis[4]
- active ankylosing spondylitis (FDA-approved Aug 2019)[3][4]
Dosage
- 75-150 mg SQ
Adverse effects
- injection site reactions
- Tinea
- upper respiratory tract infections
- neutropenia
- development or worsening of inflammatory bowel disease have been reported[2][4]
Mechanism of action
- humanized monoclonal antibody[4]
- IL17A antibody (similar to brodalumab)
More general terms
References
- ↑ Leonardi C et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012 Mar 29; 366:1190. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22455413
- ↑ 2.0 2.1 2.2 Brooks M Ixekizumab (Taltz ) for Plaque Psoriasis Clears FDA Medscape Oncology. March 22, 2016 http://www.medscape.com/viewarticle/860774
FDA News Release. March 22, 2016 FDA approves new psoriasis drug Taltz http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491872.htm - ↑ 3.0 3.1 Brooks M FDA OKs Ixekizumab (Taltz) for Active Ankylosing Spondylitis. Medscape. Aug 26, 2019. https://www.medscape.com/viewarticle/917267
- ↑ 4.0 4.1 4.2 4.3 4.4 Medical Knowledge Self Assessment Program (MKSAP) 19 American College of Physicians, Philadelphia 2022